Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 17
2003 14
2004 15
2005 20
2006 20
2007 18
2008 19
2009 29
2010 21
2011 16
2012 23
2013 23
2014 24
2015 29
2016 23
2017 30
2018 26
2019 26
2020 23
2021 23
2022 29
2023 26
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

440 results

Results by year

Filters applied: . Clear all
Page 1
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database.
Brown JR, Ghia P, Jurczak W, Kahl BS, Lamanna N, Robak T, Shadman M, Tam CS, Qiu L, Paik J, Salmi T, Wang L, Zhang J, Zhang M, Cohen A, Ma H, Tedeschi A. Brown JR, et al. Among authors: robak t. Haematologica. 2024 Feb 29. doi: 10.3324/haematol.2023.283846. Online ahead of print. Haematologica. 2024. PMID: 38426293 Free article. No abstract available.
An elevated systemic inflammation index is related to an inferior response to pomalidomide and dexamethasone treatment in patients with relapsed and refractory multiple myeloma.
Mikulski D, Robak P, Mirocha G, Ryżewska W, Stańczak K, Okoński K, Kościelny K, Robak T. Mikulski D, et al. Among authors: robak t. Contemp Oncol (Pozn). 2023;27(3):139-146. doi: 10.5114/wo.2023.133506. Epub 2023 Dec 6. Contemp Oncol (Pozn). 2023. PMID: 38239862 Free PMC article.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
440 results